Bristol Myers Squibb reports data from trial of Breyanzi for CLL
Data from the TRANSCEND CLL 004 trial showed that the study met the primary endpoint of complete response rate.
Post
AC Immune reports positive data from Alzheimer’s disease vaccine trial
At week six, the ACI-24.060 vaccine elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort of AD patients.
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
According to GlobalData’s Pharmaceutical Intelligence Center, obeticholic acid currently has a 64% likelihood of FDA approval.
Mapping endpoints: building gene therapy trials for the future
How can gene therapy trials choose the best endpoints to navigate development and demonstrate patient value?
Predictive analytics in drug development: state of play
From bypassing animal testing to forecasting outcomes, we review some of the latest use cases of predictive analytics in drug development.
Small Pharma’s depressive disorder therapy trial meets primary goal
The trial assessed the safety and efficacy of IV SPL026 with supportive therapy in 34 MDD patients.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Major depressive disorder is strongly associated with multiple sclerosis
Studies have shown MDD can worsen multiple sclerosis symptoms, reduce quality of life, and accelerate death in patients.
Wegovy: the latest weight loss fad
Elon Musk has espoused Novo Nordisk’s Wegovy to his Twitter followers, with Kim Kardashian also rumoured to have used the drug.
MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients
DB-OTO is being developed by Decibel, in partnership with Regeneron Pharmaceuticals.
Aculys Pharma starts Phase III EDS therapy trial
The trial will assess pitolisant’s efficacy and safety in Japanese OSAS patients who are complaining of EDS.
Dyadic initiates subject dosing in Phase I trial of Covid-19 booster
The trial will include healthy subjects aged 18 to 55 years who will be randomised in 4:1 ratio, with 15 subjects per cohort.
2023 starts off with a surge in clinical trials tackling pain
Tris Pharma and Wex Pharmaceuticals are two of the companies with novel therapies for pain currently undergoing clinical trials.
Global malaria infections and deaths remained stable in 2021
Malaria is mosquito-bourne disease caused by infection with the Plasmodium parasite.
AltruBio doses first subject in Phase I ulcerative colitis therapy trial
ALTB-268 helps to restore the immune system to a state of balance.
Benitec Biopharma begins OPMD subject enrolment
The NH study will enable the characterisation of OPMD patient disposition at baseline.
Renexxion reveals clinical development plans to address GI symptoms in cystic fibrosis patients
CEO Dr Peter Milner previews the clinical trials that will investigate naronapride for the treatment of GI dysmotility in the cystic fibrosis population.